# Lutetium-177

Source: https://nuclide.cc/isotopes/lu-177/  
Nuclide record `lu-177` (Isotope). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A radioactive metal that gives off short-range radiation. Attached to a molecule that sticks to a tumour, it irradiates the tumour from the inside while sparing most healthy tissue.

## Summary

Lutetium-177 is the workhorse therapeutic radionuclide of the theranostic era, carried by DOTATATE (Lutathera, neuroendocrine tumours) and PSMA-617 (Pluvicto, prostate cancer). Its 6.65-day half-life and roughly 0.5-2 mm beta range let it be shipped internationally and deliver a dose that matches small-to-medium tumour deposits.

Its 208 keV gamma emission is imageable, so the same injection that treats the patient can be used for post-therapy SPECT and dosimetry. It can be made carrier-added by direct neutron capture on 176Lu, or no-carrier-added (higher specific activity) via 176Yb(n,γ)177Yb, which decays to 177Lu; the latter avoids the long-lived 177mLu impurity but needs scarce enriched 176Yb.

Demand rose sharply after Pluvicto's 2022 approval, straining the small number of high-flux research reactors (BR2, HFR, Maria, SAFARI-1 and others) and the Russian-dominated supply of enriched ytterbium-176. Shortages in 2022-2023 delayed some Pluvicto doses; new capacity (Bruce Power/Isogen in Canadian CANDU reactors, SHINE's accelerator route) has since expanded supply.

## Fields

- Kind: Isotope
- Status: approved
- Last checked: 2026-09-22
- Also known as: 177Lu; Lu-177
- Tags: therapy; beta emitter

## Sources

- Challenges and future options for the production of lutetium-177 (EJNMMI Radiopharm Chem, 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC8241800/
- FDA label: Pluvicto (lutetium Lu 177 vipivotide tetraxetan): https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf
- OECD-NEA: Current trends in the supply and utilisation of medical radioisotopes (2025): https://www.oecd-nea.org/upload/docs/application/pdf/2025-10/7743_medical_radioisotopes_supply_rev.pdf

## Connected records

- drugs: [177Lu-edotreotide](https://nuclide.cc/drugs/itm-11/), [177Lu-PSMA-I&T](https://nuclide.cc/drugs/lu177-psma-it/), [AAA817](https://nuclide.cc/drugs/aaa817/), [Actinium-225 DOTATATE](https://nuclide.cc/drugs/ryz101/), [Cabazitaxel](https://nuclide.cc/drugs/cabazitaxel/), [FAP-2286 (177Lu / 68Ga)](https://nuclide.cc/drugs/fap-2286/), [Florastamin F-18](https://nuclide.cc/drugs/florastamin-f18/), [Flotufolastat F-18](https://nuclide.cc/drugs/flotufolastat/), [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://nuclide.cc/drugs/ga68-dotatate/), [Gallium-68 edotreotide (DOTATOC)](https://nuclide.cc/drugs/ga-68-dotatoc/), [Gallium-68 gozetotide (PSMA-11)](https://nuclide.cc/drugs/ga68-psma-11/), [Iobenguane I-131 (therapeutic)](https://nuclide.cc/drugs/iobenguane-i-131/), [Locametz (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/locametz/), [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/), [Lutetium-177 dotatate (radioligand equivalent)](https://nuclide.cc/drugs/lu-177-dotatate-generic/), [Lutetium-177 PNT2002](https://nuclide.cc/drugs/lu-177-pnt2002/), [Lutetium-177 rosopatamab tetraxetan](https://nuclide.cc/drugs/tlx-591/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/), [Radium-223 dichloride](https://nuclide.cc/drugs/radium-223/)
- technologies: [Albumin-binder ligands](https://nuclide.cc/technologies/albumin-binder-ligands/), [Auger-electron therapy](https://nuclide.cc/technologies/auger-electron-therapy/), [Automated synthesis modules](https://nuclide.cc/technologies/automated-synthesis-modules/), [CAIX PET (89Zr-girentuximab)](https://nuclide.cc/technologies/caix-pet/), [DOTA chelation](https://nuclide.cc/technologies/dota-chelation/), [Hot cells and radiation shielding](https://nuclide.cc/technologies/hot-cells-and-shielding/), [Lutetium-177 radioligand therapy](https://nuclide.cc/technologies/lu177-radioligand-therapy/), [Monte Carlo dosimetry](https://nuclide.cc/technologies/monte-carlo-dosimetry/), [Peptide receptor radionuclide therapy (PRRT)](https://nuclide.cc/technologies/prrt/), [Pretargeted radioimmunotherapy](https://nuclide.cc/technologies/pretargeted-radioimmunotherapy/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Quantitative SPECT](https://nuclide.cc/technologies/quantitative-spect/), [Radio-antibody & radio-ADC](https://nuclide.cc/technologies/radioimmunotherapy/), [Radiohybrid (rh) chemistry](https://nuclide.cc/technologies/radiohybrid-chemistry/), [Radiolabelling quality control](https://nuclide.cc/technologies/radiolabelling-quality-control/), [Radioligand plus DNA-repair inhibitor combinations](https://nuclide.cc/technologies/radionuclide-parp-combination/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://nuclide.cc/technologies/radiopharmaceutical-gmp-release/), [Radiopharmacy and cyclotron networks](https://nuclide.cc/technologies/radiopharmacy-network/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://nuclide.cc/technologies/research-reactor-isotope-production/), [SPECT & bone scan](https://nuclide.cc/technologies/spect/), [SPECT dosimetry workflow for radionuclide therapy](https://nuclide.cc/technologies/spect-dosimetry-workflow/), [SPECT/CT](https://nuclide.cc/technologies/spect-ct/), [Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)](https://nuclide.cc/technologies/therapy-isotope-supply-chain/)
- indications: [Grade 3 well-differentiated neuroendocrine tumour](https://nuclide.cc/indications/grade-3-net/), [Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)](https://nuclide.cc/indications/hereditary-ppgl/), [Lung neuroendocrine tumours (typical and atypical carcinoid)](https://nuclide.cc/indications/lung-net/), [Metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-mcrpc/), [Metastatic hormone-sensitive prostate cancer](https://nuclide.cc/indications/prostate-mhspc/), [Metastatic pheochromocytoma and paraganglioma](https://nuclide.cc/indications/metastatic-ppgl/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://nuclide.cc/indications/multiple-endocrine-neoplasia/), [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Pancreatic neuroendocrine tumours](https://nuclide.cc/indications/pancreatic-net/), [Pheochromocytoma and paraganglioma (PPGL)](https://nuclide.cc/indications/pheochromocytoma-paraganglioma/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Small intestinal neuroendocrine tumours](https://nuclide.cc/indications/small-intestinal-net/)
- targets: [5T4 (trophoblast glycoprotein)](https://nuclide.cc/targets/tpbg-5t4/), [CCK2 receptor (gastrin receptor)](https://nuclide.cc/targets/cck2-receptor/), [CXCR4](https://nuclide.cc/targets/cxcr4/), [FAP](https://nuclide.cc/targets/fap/), [GRPR (gastrin-releasing peptide receptor)](https://nuclide.cc/targets/grpr/), [PSMA](https://nuclide.cc/targets/psma/), [Somatostatin receptor 2](https://nuclide.cc/targets/sstr2/), [Sortilin (SORT1)](https://nuclide.cc/targets/sortilin/)
- companies: [Advanced Accelerator Applications (Novartis)](https://nuclide.cc/companies/advanced-accelerator-applications/), [Alpha-9 Oncology](https://nuclide.cc/companies/alpha-9-oncology/), [ANSTO (Australian Nuclear Science and Technology Organisation)](https://nuclide.cc/companies/ansto/), [ARTBIO](https://nuclide.cc/companies/artbio/), [Bracco Imaging](https://nuclide.cc/companies/bracco/), [BWXT Medical](https://nuclide.cc/companies/bwxt-medical/), [CellBion](https://nuclide.cc/companies/cellbion/), [Convergent Therapeutics](https://nuclide.cc/companies/convergent-therapeutics/), [Curium](https://nuclide.cc/companies/curium/), [DuChemBio](https://nuclide.cc/companies/duchembio/), [Eckert & Ziegler](https://nuclide.cc/companies/eckert-ziegler/), [Full-Life Technologies](https://nuclide.cc/companies/full-life-technologies/), [HTA (Atom Hi-Tech)](https://nuclide.cc/companies/hta-atom-hi-tech/), [IRE (Institut national des Radioéléments)](https://nuclide.cc/companies/ire/), [Isotopia Molecular Imaging](https://nuclide.cc/companies/isotopia/), [ITM Isotope Technologies Munich](https://nuclide.cc/companies/itm/), [Lantheus](https://nuclide.cc/companies/lantheus/), [Life Molecular Imaging](https://nuclide.cc/companies/life-molecular-imaging/), [MIM Software (GE HealthCare)](https://nuclide.cc/companies/mim-software/), [Molecular Targeting Technologies](https://nuclide.cc/companies/molecular-targeting-technologies/), [Niowave](https://nuclide.cc/companies/niowave/), [NorthStar Medical Radioisotopes](https://nuclide.cc/companies/northstar-medical-radioisotopes/), [Novartis](https://nuclide.cc/companies/novartis/), [NTP Radioisotopes](https://nuclide.cc/companies/ntp-radioisotopes/), [Nuclidium](https://nuclide.cc/companies/nuclidium/), [Radiopharm Theranostics](https://nuclide.cc/companies/radiopharm-theranostics/), [SHINE Technologies](https://nuclide.cc/companies/shine-technologies/), [Sinotau Pharmaceutical](https://nuclide.cc/companies/sinotau-pharmaceutical/), [Telix Pharmaceuticals](https://nuclide.cc/companies/telix/), [Trasis](https://nuclide.cc/companies/trasis/), [Y-mAbs Therapeutics](https://nuclide.cc/companies/y-mabs/)
- institutions: [ANZUP Cancer Trials Group](https://nuclide.cc/institutions/anzup/), [Board of Radiation and Isotope Technology](https://nuclide.cc/institutions/brit/), [Erasmus MC Cancer Institute](https://nuclide.cc/institutions/erasmus-mc/), [European Association of Nuclear Medicine](https://nuclide.cc/institutions/eanm/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://nuclide.cc/institutions/irst-meldola/), [Korean Society of Nuclear Medicine](https://nuclide.cc/institutions/ksnm/), [Peter MacCallum Cancer Centre](https://nuclide.cc/institutions/peter-mac/)
- pathways: [Prostate cancer (KEGG map)](https://nuclide.cc/pathways/prostate-cancer-signalling/)
- terms: [Activity prescription: fixed versus dosimetry-guided dosing](https://nuclide.cc/terms/activity-prescription/), [Alpha vs beta emitters](https://nuclide.cc/terms/alpha-vs-beta/), [Attenuation correction](https://nuclide.cc/terms/attenuation-correction/), [Authorized User (AU)](https://nuclide.cc/terms/authorized-user/), [Becquerel and curie (units of radioactivity)](https://nuclide.cc/terms/becquerel-curie/), [Biological half-life](https://nuclide.cc/terms/biological-half-life/), [Chelator (bifunctional chelating agent)](https://nuclide.cc/terms/chelator-term/), [Crossover in trials](https://nuclide.cc/terms/crossover/), [Cytopenias and myelosuppression](https://nuclide.cc/terms/cytopenias/), [Effective half-life](https://nuclide.cc/terms/effective-half-life/), [Fixed versus personalised (dosimetry-guided) dosing](https://nuclide.cc/terms/fixed-versus-personalised-dosing/), [Gray unit (Gy)](https://nuclide.cc/terms/gray-unit/), [Half-life](https://nuclide.cc/terms/half-life/), [Krenning score](https://nuclide.cc/terms/krenning-score/), [Linear energy transfer (LET)](https://nuclide.cc/terms/linear-energy-transfer/), [mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)](https://nuclide.cc/terms/mcrpc-mhspc/), [Myelosuppression after radioligand therapy](https://nuclide.cc/terms/myelosuppression-after-rlt/), [No-carrier-added (n.c.a.) and carrier-added production](https://nuclide.cc/terms/no-carrier-added/), [Partial volume effect (PVE)](https://nuclide.cc/terms/partial-volume-effect/), [Patient release criteria after radioactive treatment](https://nuclide.cc/terms/patient-release-criteria/), [PRRT (peptide receptor radionuclide therapy)](https://nuclide.cc/terms/prrt-term/), [PSMA-RADS (PSMA reporting and data system)](https://nuclide.cc/terms/psma-rads/), [Radiochemical purity (RCP)](https://nuclide.cc/terms/radiochemical-purity/), [Radiolysis (self-radiolysis of radiopharmaceuticals)](https://nuclide.cc/terms/radiolysis/), [Relative biological effectiveness (RBE)](https://nuclide.cc/terms/relative-biological-effectiveness/), [Renal protection with amino acid co-infusion](https://nuclide.cc/terms/renal-protection-amino-acids/), [Salivary gland toxicity (xerostomia) from PSMA radioligand therapy](https://nuclide.cc/terms/salivary-gland-toxicity/), [SDH deficiency (SDHB immunohistochemistry loss)](https://nuclide.cc/terms/sdh-deficiency/), [Theranostic pair](https://nuclide.cc/terms/theranostic-pair-term/), [Theranostics](https://nuclide.cc/terms/theranostics/), [Time-activity curve (TAC)](https://nuclide.cc/terms/time-activity-curve/)
- trials: [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://nuclide.cc/trials/nct07189871/), [A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms](https://nuclide.cc/trials/nct06398444/), [A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer](https://nuclide.cc/trials/nct06184035/), [A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy](https://nuclide.cc/trials/nct05547061/), [A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC](https://nuclide.cc/trials/nct06383052/), [A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.](https://nuclide.cc/trials/nct06247995/), [A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA](https://nuclide.cc/trials/nct07226986/), [A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs](https://nuclide.cc/trials/nct05459844/), [A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer](https://nuclide.cc/trials/nct05658003/), [A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab](https://nuclide.cc/trials/nct05142696/), [A Study of 177Lu-FAP-2286 in Advanced Solid Tumors](https://nuclide.cc/trials/nct04939610/), [A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/nct07047118/), [A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors](https://nuclide.cc/trials/nct05706129/), [ACTION-1](https://nuclide.cc/trials/action-1/), [An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.](https://nuclide.cc/trials/nct05884255/), [An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.](https://nuclide.cc/trials/nct05939414/), [An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC](https://nuclide.cc/trials/nct06894511/), [Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection](https://nuclide.cc/trials/nct05413850/), [COMPETE](https://nuclide.cc/trials/compete/), [ECLIPSE](https://nuclide.cc/trials/eclipse-psma/), [ENZA-p](https://nuclide.cc/trials/enza-p/), [Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)](https://nuclide.cc/trials/nct07357519/), [LuTectomy](https://nuclide.cc/trials/lutectomy/), [Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE](https://nuclide.cc/trials/nct04919226/), [NETTER-1](https://nuclide.cc/trials/netter-1/), [ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC](https://nuclide.cc/trials/nct05682443/), [Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy](https://nuclide.cc/trials/nct06780670/), [Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer](https://nuclide.cc/trials/nct06139575/), [Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC](https://nuclide.cc/trials/nct07197580/), [PRINCE](https://nuclide.cc/trials/prince-trial/), [PSMAddition](https://nuclide.cc/trials/psmaddition/), [PSMAfore](https://nuclide.cc/trials/psmafore/), [SPLASH](https://nuclide.cc/trials/splash/), [Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function](https://nuclide.cc/trials/nct06004661/), [Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs](https://nuclide.cc/trials/nct04711135/), [Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET](https://nuclide.cc/trials/nct06784752/), [Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET](https://nuclide.cc/trials/nct03972488/), [The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)](https://nuclide.cc/trials/nct06520345/), [TheraP (ANZUP 1603)](https://nuclide.cc/trials/therap/), [UpFrontPSMA](https://nuclide.cc/trials/upfront-psma/), [VISION](https://nuclide.cc/trials/vision/)
- pairings: [177Lu-PSMA-617 (Pluvicto) with olaparib](https://nuclide.cc/pairings/pluvicto-plus-olaparib/), [177Lu-PSMA-617 then 225Ac-PSMA rescue therapy](https://nuclide.cc/pairings/beta-psma-then-alpha-psma-rescue/), [68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)](https://nuclide.cc/pairings/ga68-dotatate-then-lutathera/), [Beta PRRT → alpha PRRT](https://nuclide.cc/pairings/prrt-then-alpha-net/), [Beta radioligand → alpha radioligand](https://nuclide.cc/pairings/beta-then-alpha/), [Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617](https://nuclide.cc/pairings/docetaxel-then-lu177-psma/), [PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)](https://nuclide.cc/pairings/prrt-plus-captem/), [PSMA PET → PSMA radioligand therapy](https://nuclide.cc/pairings/psma-pet-to-rlt/), [SSTR PET → PRRT](https://nuclide.cc/pairings/sstr-pet-to-prrt/)
- ideas: [A coordinated reserve and shared schedule for the world's medical isotope reactors](https://nuclide.cc/ideas/idea-reg-medical-isotope-reactor-reserve/), [A global medical isotope supply observatory with forecasts and shortage alerts](https://nuclide.cc/ideas/idea-reg-isotope-supply-observatory/), [A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment](https://nuclide.cc/ideas/idea-copper-theranostic-pair-standard/), [A university cyclotron network with shared regulatory files for new tracers](https://nuclide.cc/ideas/idea-fund-academic-radiopharma-pipeline/), [Adding a checkpoint inhibitor to PSMA radioligand therapy](https://nuclide.cc/ideas/idea-rlt-plus-checkpoint-inhibitor/), [Adding a PARP inhibitor to PSMA radioligand therapy](https://nuclide.cc/ideas/idea-rlt-plus-parp-inhibitor/), [AI segmentation to make voxel-level radioligand dosimetry practical at scale](https://nuclide.cc/ideas/idea-ai-lesion-segmentation-dosimetry/), [Alpha radioligands after ADC failure](https://nuclide.cc/ideas/idea-alpha-after-adc/), [Alpha-emitting PSMA therapy at first metastatic diagnosis](https://nuclide.cc/ideas/idea-alpha-first-mhspc/), [Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer](https://nuclide.cc/ideas/idea-alpha-for-oligometastatic-disease/), [Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions](https://nuclide.cc/ideas/idea-bispecific-radioligands/), [Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier](https://nuclide.cc/ideas/idea-reg-yb176-enrichment-capacity/), [CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy](https://nuclide.cc/ideas/idea-caix-theranostics/), [Dosimetry-personalised PRRT instead of four fixed cycles](https://nuclide.cc/ideas/idea-net-dosimetry-prrt/), [FAP-targeted radioligand therapy for sarcoma](https://nuclide.cc/ideas/idea-fap-theranostics-sarcoma/), [In-house hospital radiopharmacy compounding to cut dose waste](https://nuclide.cc/ideas/idea-regional-radiopharmacy-network/), [Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy](https://nuclide.cc/ideas/idea-dosimetry-guided-dosing-standard/), [Neoadjuvant PSMA radioligand therapy before prostatectomy](https://nuclide.cc/ideas/idea-neoadjuvant-psma-therapy/), [Pretargeted alpha radioimmunotherapy](https://nuclide.cc/ideas/idea-pretargeted-alpha-therapy/), [SSTR antagonist radioligands to increase tumour dose](https://nuclide.cc/ideas/idea-net-antagonist-ligands/), [Terbium-161 instead of lutetium-177 in the same ligands](https://nuclide.cc/ideas/idea-tb161-instead-of-lu177/), [Total-body PET for personalised radioligand dosing](https://nuclide.cc/ideas/idea-total-body-pet-dosimetry/)
- people: [A. Oliver Sartor](https://nuclide.cc/people/oliver-sartor/), [Amir Iravani](https://nuclide.cc/people/amir-iravani/), [Dale L. Bailey](https://nuclide.cc/people/dale-bailey/), [Emily K. Bergsland](https://nuclide.cc/people/emily-bergsland/), [Erik S. Mittra](https://nuclide.cc/people/erik-mittra/), [Jeremie Calais](https://nuclide.cc/people/jeremie-calais/), [Johannes Czernin](https://nuclide.cc/people/johannes-czernin/), [Jonathan R. Strosberg](https://nuclide.cc/people/jonathan-strosberg/), [Ken Herrmann](https://nuclide.cc/people/ken-herrmann/), [Lisa Bodei](https://nuclide.cc/people/lisa-bodei/), [Louise Emmett](https://nuclide.cc/people/louise-emmett/), [Michael Hofman](https://nuclide.cc/people/hofman-michael/), [Michael J. Morris](https://nuclide.cc/people/michael-morris/), [Michael Lassmann](https://nuclide.cc/people/michael-lassmann/), [Peter Bartenstein](https://nuclide.cc/people/peter-bartenstein/), [Phillip H. Kuo](https://nuclide.cc/people/phillip-kuo/), [Rahul Aggarwal](https://nuclide.cc/people/rahul-aggarwal/), [Richard P. Baum](https://nuclide.cc/people/richard-baum/), [Rodney J. Hicks](https://nuclide.cc/people/rodney-hicks/), [Scott T. Tagawa](https://nuclide.cc/people/scott-tagawa/), [Shahneen Sandhu](https://nuclide.cc/people/sandhu-shahneen/), [Simron Singh](https://nuclide.cc/people/simron-singh/), [Uwe Haberkorn](https://nuclide.cc/people/uwe-haberkorn/), [Wolfgang P. Fendler](https://nuclide.cc/people/wolfgang-fendler/)
- bottlenecks: [Authorized user shortage for radionuclide therapy](https://nuclide.cc/bottlenecks/b-authorized-user-shortage/), [Clinical trial capacity for radioligand therapy](https://nuclide.cc/bottlenecks/b-rlt-trial-capacity/), [Dosimetry standardisation for radioligand therapy](https://nuclide.cc/bottlenecks/b-dosimetry-standardisation/), [Enriched target material for therapeutic isotopes](https://nuclide.cc/bottlenecks/b-enriched-target-material/), [Hot lab and shielded treatment room capacity](https://nuclide.cc/bottlenecks/b-hot-lab-capacity/), [Manufacturing cost and time for living and radioactive medicines](https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/), [Radioactive waste handling and disposal regulation](https://nuclide.cc/bottlenecks/b-radioactive-waste-regulation/), [Site readiness and referral pathway delays](https://nuclide.cc/bottlenecks/b-site-readiness-referral/)
- key papers: [225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-kratochwil-ac225-psma-jnm-2016/), [EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands](https://nuclide.cc/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/), [Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate](https://nuclide.cc/key-papers/paper-strosberg-netter1-qol-jco-2018/), [LuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-hofman-lupsma-lancet-oncol-2018/), [NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide](https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/), [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/), [Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC](https://nuclide.cc/key-papers/paper-tagawa-ac225-j591-jco-2024/), [PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC](https://nuclide.cc/key-papers/paper-psmafore-lancet-2024/), [Radiopharmaceutical therapy in cancer: clinical advances and challenges](https://nuclide.cc/key-papers/paper-sgouros-tat-review-nat-rev-2020/), [Radiotheranostics: a roadmap for future development](https://nuclide.cc/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/), [Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms](https://nuclide.cc/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/), [TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer](https://nuclide.cc/key-papers/paper-therap-lancet-2021/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- journals: [Journal of Nuclear Medicine](https://nuclide.cc/journals/journal-of-nuclear-medicine/), [Nuclear Medicine and Molecular Imaging](https://nuclide.cc/journals/nuclear-medicine-and-molecular-imaging/)
- opportunities: [DLL3 imaging for small-cell lung cancer](https://nuclide.cc/opportunities/opp-dll3-imaging-sclc/), [FAP imaging to stop futile pancreatic surgery](https://nuclide.cc/opportunities/opp-fap-pancreatic-staging/), [GRPR imaging when the PSMA scan is negative](https://nuclide.cc/opportunities/opp-grpr-psma-negative-prostate/)
- collections: [OpenDose](https://nuclide.cc/collections/opendose/), [SNMMI Procedure Standards](https://nuclide.cc/collections/snmmi-procedure-standards/), [US NRC 10 CFR Part 35 (Medical Use of Byproduct Material)](https://nuclide.cc/collections/nrc-regulations-part35/)
- fronts: [Dosimetry](https://nuclide.cc/fronts/f-dosimetry/), [Isotope supply](https://nuclide.cc/fronts/f-isotope-supply/), [Radiochemistry & manufacturing](https://nuclide.cc/fronts/f-radiochemistry/), [Radioligand therapy](https://nuclide.cc/fronts/f-radioligand-therapy/), [Targeted alpha therapy](https://nuclide.cc/fronts/f-alpha-therapy/)
- isotopes: [Scandium-47](https://nuclide.cc/isotopes/sc-47/), [Terbium-161](https://nuclide.cc/isotopes/tb-161/)
- roadmaps: [Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline](https://nuclide.cc/roadmaps/alpha-therapy-roadmap/), [Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose](https://nuclide.cc/roadmaps/dosimetry-roadmap/), [Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium](https://nuclide.cc/roadmaps/isotope-supply-roadmap/), [PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha](https://nuclide.cc/roadmaps/psma-theranostics-roadmap/), [SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha](https://nuclide.cc/roadmaps/sstr-theranostics-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/lu-177.json